Evazarsen sodium
{{Orphan|date=December 2023}}
{{Infobox drug
| drug_name = Evazarsen sodium
| synonyms = IONIS-AGT-LRx
| INN =
| type =
| image =
| alt =
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status = Investigational
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number = 2589926-24-7
| UNII = W3077QR2KG
| PubChem =
| DrugBank =
| IUPAC_name =
| chemical_formula =
| molecular_weight =
}}
Evazarsen sodium (IONIS-AGT-LRx) is an antisense RNA designed to inhibit angiotensinogen as an alternative to other mechanisms to target the renin–angiotensin–aldosterone system.{{cite journal |last1=Kahlon |first1=Tanvir |last2=Carlisle |first2=Samantha |last3=Otero Mostacero |first3=Diana |last4=Williams |first4=Nina |last5=Trainor |first5=Patrick |last6=DeFilippis |first6=Andrew P. |title=Angiotensinogen |journal=JACC: Heart Failure |date=October 2022 |volume=10 |issue=10 |pages=699–713 |doi=10.1016/j.jchf.2022.06.005|doi-access=free |pmid=35963818 }}{{cite journal |last1=Fernández-Ruiz |first1=Irene |title=An antisense oligonucleotide to target the RAAS |journal=Nature Reviews Cardiology |date=August 2021 |volume=18 |issue=8 |pages=544 |doi=10.1038/s41569-021-00574-9 |pmid=34040182 |url=https://www.nature.com/articles/s41569-021-00574-9 |language=en |issn=1759-5010|url-access=subscription }}{{cite journal |last1=Morgan |first1=Erin S. |last2=Tami |first2=Yvonne |last3=Hu |first3=Kuolung |last4=Brambatti |first4=Michela |last5=Mullick |first5=Adam E. |last6=Geary |first6=Richard S. |last7=Bakris |first7=George L. |last8=Tsimikas |first8=Sotirios |title=Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx |journal=JACC: Basic to Translational Science |date=June 2021 |volume=6 |issue=6 |pages=485–496 |doi=10.1016/j.jacbts.2021.04.004|doi-access=free |pmid=34222719 |pmc=8246029 }}